FDA approves COVID boosters for 6-month-olds, citing trial with just 24 patients

FDA approves COVID boosters for 6-month-olds, citing trial with just 24 patients --One prominent jab critic called it a 'new low' for the FDA. | 17 March 2023 | The U.S. Food & Drug Administration (FDA) is approving booster doses of Pfizer's COVID-19 shot for children as young as six months based on a trial of just 24 patients. The FDA announced March 14 that it is amending its emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, Bivalent, to allow a single booster dose for children between six months and four years, at least two months after being initially vaccinated... Buried in the press release, however, was the revelation that "among individuals 6 months of age and older, safety was assessed in participants in two clinical studies," and that for the 6-23 months age group there were only 24 participants. The 2-4 year age group had 36. Medical freedom attorney and COVID vaccine critic Aaron Siri called it a "new low" for the FDA to make its decision based on such limited data.